Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by collection
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by collection
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Immune-related adverse events (irAEs)
Email alerts
Immune-related adverse events (irAEs)
Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab
Matthew
Zibelman
,
Natasha
Pollak
,
Anthony J
Olszanski
Journal for ImmunoTherapy of Cancer
Dec 2016,
4
(1)
8;
DOI:
10.1186/s40425-016-0114-4
Opportunistic infections in patients treated with immunotherapy for cancer
Chrisann
Kyi
,
Matthew D
Hellmann
,
Jedd D
Wolchok
,
Paul B
Chapman
,
Michael A
Postow
Journal for ImmunoTherapy of Cancer
Dec 2014,
2
(1)
19;
DOI:
10.1186/2051-1426-2-19
Ipilimumab in patients with melanoma and autoimmune disease
Chrisann
Kyi
,
Richard D
Carvajal
,
Jedd D
Wolchok
,
Michael A
Postow
Journal for ImmunoTherapy of Cancer
Dec 2014,
2
(1)
35;
DOI:
10.1186/s40425-014-0035-z
Special collections
COVID-19
(44)
Editor's choice
JITC
Aging and diversity, equity, and inclusion (DEI) with regard to cancer immunotherapy and understudied populations
Aging and diversity, equity, and inclusion (DEI) with regard to cancer immunotherapy and understudied populations
Basic Tumor Immunology
(538)
Case Reports
(191)
Clinical Trials Monitor
(17)
Clinical/Translational Cancer Immunotherapy
(941)
Commentary/Editorials
(142)
Computational I-O
(4)
COVID-19 and Cancer Immunotherapy
(10)
Emerging Immunotherapeutic Agents
(5)
Guidelines and Consensus Statements
(55)
Guidelines and Consensus Statements
(50)
Imaging and Immunotherapy
(8)
Immune Cell Therapies and Immune Cell Engineering
(214)
Immune Checkpoints - Beyond PD-1
(8)
Immune Checkpoints Beyond PD-1 Series
(8)
Immune Monitoring Technology Primers
(12)
Immunotherapy Biomarkers
(409)
Liquid Biopsies
(9)
Microbial-Based Cancer Immunotherapy
(4)
Oncolytic and Local Immunotherapy
(144)
Reviews
(239)
Open access
(4877)
Press releases
